The edict came out of concern for players suffering injuries from foul play, but acted as the most unfortunate prediction for Friday night s controversy at Bankwest Stadium. Eels stars Dylan Brown and Marata Niukore were both allowed to stay on the field despite two incidents of foul play that is now set to cost them time on the sidelines.
Cameron Spencer/Getty Images
Roosters coach Trent Robinson didn’t hold back after his side’s defeat to the Eels. Brown s sliding knees in a tackle sent Roosters half Drew Hutchison to hospital with broken ribs and a possible punctured lung, while Niukore was put on report for two shoulder charges within a minute.
âExtremely unhappyâ: NRL axes refs after Roosters debacle The bunker officials from Friday nightâs controversial Roosters and Eels clash have copped the wrath of the NRL, as Graham Annesley revealed his displeasure.
Rugby League by Paul Crawley
Premium Content
Subscriber only The NRL has reacted swiftly to the officiating howlers in Friday night s Eels-Roosters match by axing the bunker officials who failed to act on a number of controversial incidents. NRL head of football Graham Annesley said he was extremely unhappy with several decisions from the bunker, led by senior review official Steve Chiddy, adding that their performance did not meet our expectations .
Share:
SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectra® test, from Myriad Autoimmune s business unit to Labcorp (NYSE:LH) for $150 million in cash. Labcorp is a leading global life sciences company and one of the nation s largest laboratory service providers. Our agreement with Labcorp meets our goals of ensuring broad access to the Vectra® test for patients, ensuring a good home for our teammates, and delivering strong value for our shareholders, said Paul J. Diaz, president and CEO of Myriad Genetics. While we are strong believers in the future growth prospects for Vectra, this divestiture will allow us to increase operational focus and better execute in our core strategic businesses of Women s Health, Oncology, and Mental Health.